Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Revenue (2017 - 2025)

Sutro Biopharma's Revenue history spans 9 years, with the latest figure at $9.7 million for Q3 2025.

  • For Q3 2025, Revenue rose 13.77% year-over-year to $9.7 million; the TTM value through Sep 2025 reached $105.6 million, down 30.97%, while the annual FY2024 figure was $62.0 million, 59.64% down from the prior year.
  • Revenue for Q3 2025 was $9.7 million at Sutro Biopharma, down from $75.4 million in the prior quarter.
  • Across five years, Revenue topped out at $113.7 million in Q4 2023 and bottomed at $5.7 million in Q1 2025.
  • The 5-year median for Revenue is $13.0 million (2024), against an average of $22.5 million.
  • The largest annual shift saw Revenue skyrocketed 1217.44% in 2023 before it tumbled 86.98% in 2024.
  • A 5-year view of Revenue shows it stood at $10.7 million in 2021, then fell by 18.98% to $8.6 million in 2022, then surged by 1217.44% to $113.7 million in 2023, then crashed by 86.98% to $14.8 million in 2024, then crashed by 34.55% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Revenue are $9.7 million (Q3 2025), $75.4 million (Q2 2025), and $5.7 million (Q1 2025).